Structural and pharmaceutical studies on a novel human protein, MIC-1

新型人类蛋白质 MIC-1 的结构和药学研究

• 批准号: LP0883838
• 负责人: Prof Paul Curmi
• 金额: $ 36.04万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-06-30 至 2012-06-29
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0883838
• 关键词: Structural; pharmaceutical; studies; novel; human

Cancer and obesity are two of the main health problems facing Australia, as reflected by the National Research Priority: Promoting and Maintaining Good Health. This project will develop new diagnostic tools for early cancer detection and prognosis using the protein, MIC-1. MIC-1 is responsible for cachexia, a wasting disorder responsible for 25% of cancer deaths, which has no effective therapy. MIC-1 and antibodies neutralising MIC-1 may provide therapeutic agents to control cancer cachexia and severe obesity. The project will optimise these molecules for therapeutic uses. These diagnostic and therapeutic tools will form the basis of a spin-off company for commercialisation.

癌症和肥胖是澳大利亚面临的两个主要健康问题，这反映在国家研究重点：促进和保持良好的健康。 该项目将开发新的诊断工具，用于使用蛋白质MIC-1进行早期癌症检测和预后。 MIC-1是恶病质的原因，恶病质是一种消耗性疾病，占癌症死亡的25%，没有有效的治疗方法。MIC-1和中和MIC-1的抗体可提供控制癌症恶病质和严重肥胖的治疗剂。该项目将优化这些分子用于治疗用途。 这些诊断和治疗工具将成为一家商业化分拆公司的基础。